Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
about
Current Options for Determining Fracture UnionBone morphogenetic protein in pediatric spine fusion surgeryTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsChange in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse OutcomeA consensus statement regarding the utilization of BMP in spine surgeryPublic awareness of the bone morphogenic protein controversy: Evidence from news publicationsNanotemplated polyelectrolyte films as porous biomolecular delivery systems. Application to the growth factor BMP-2.Growth Differentiation Factor 5-Mediated Enhancement of Chondrocyte Phenotype Is Inhibited by Heparin: Implications for the Use of Heparin in the Clinic and in Tissue Engineering Applications.Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration.Accelerated postero-lateral spinal fusion by collagen scaffolds modified with engineered collagen-binding human bone morphogenetic protein-2 in ratsRecombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosisThe Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering ApplicationsHeterotopic ossification related to the use of recombinant human BMP-2 in osteonecrosis of femoral headCancer risk from bone morphogenetic protein exposure in spinal arthrodesis.The 'Ziran' wrap: reconstruction of critical-sized long bone defects using a fascial autograft and reamer-irrigator-aspirator autograftConstructing the toolbox: Patient-specific genetic factors of altered fracture healingBasic science and spine literature document bone morphogenetic protein increases cancer risk.Muscle-bone interactions during fracture healing.Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare DatabasePoint-counter-point debate: the association between recombinant human bone morphogenetic protein utilization and complications in spine surgery.Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2The Use of Bone Morphogenetic Protein in Pediatric Cervical Spine Fusion Surgery: Case Reports and Review of the Literature.Chimeric Aptamer-Gelatin Hydrogels as an Extracellular Matrix Mimic for Loading Cells and Growth Factors.PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patientsSpine interbody implants: material selection and modification, functionalization and bioactivation of surfaces to improve osseointegration.Bone morphogenetic protein-2 and vascular endothelial growth factor in bone tissue regeneration: new insight and perspectives.Bone morphogenetic proteins: a powerful osteoinductive compound with non-negligible side effects and limitations.Neoplasia following use of BMPs: is there an increased risk?Gene therapy for bone engineering.Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.Use of recombinant human bone morphogenetic protein-2 in spine surgery.Bone morphogenetic protein-2 and bone therapy: successes and pitfalls.Is the Cage an Additional Hardware in Lumbar Interbody Fusion for Low Grade Spondylolisthesis? A Prospective Study.A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.Future Advances in Spine Surgery: The AOSpine North America Perspective.Novel Osteobiologics and Biomaterials in the Treatment of Spinal Disorders.Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.Tissue engineering and regenerative medicine in musculoskeletal oncology.Encapsulation of Adenovirus BMP2-Transduced Cells with PEGDA Hydrogels Allows Bone Formation in the Presence of Immune Response.Strategies of enhancing bone regenerate formation in distraction osteogenesis.
P2860
Q27006490-71416829-5A76-459A-A804-9A3B5B74F63BQ28077548-D8D22D93-6C16-4AB4-8B45-63AFEDD54987Q28078154-ADB836D9-8F4E-407F-A125-1631A065423CQ28597004-ABF0CA4D-BCBC-4D13-8EEC-D29249B96874Q28606708-EF14DC1F-82D0-4228-9B48-8C6377BE9B2DQ28652500-5F7BEBAD-CCD3-4CA7-BE18-059555324B54Q30414105-EC16FA79-F244-46D5-9BD4-4AD398F5907AQ33580590-257FE605-EF23-495E-9129-7A76C0081FA0Q33639409-EE33FE0E-ADBA-4491-A870-70D638A61D0CQ33679554-9427753F-A802-4523-B0B4-8F277767F678Q33793675-4BB6D5AF-A3FF-410F-A84C-D910A945995FQ33851544-D48490A9-153B-48DA-848B-910C6B1314CBQ33885851-068BC880-267A-44ED-8D39-F0A408B7D887Q34087981-8CDA51D2-DDD3-4A8C-979E-050E4CC04719Q34306082-2D93FF06-F18B-4B42-9305-6A2BBC50DF2DQ34794967-856524A2-847F-4C72-A4AD-619762D52C27Q34880007-4E77E51D-7848-442A-8F33-515328E69A5EQ35612050-D409A77B-9962-45DA-A6CD-A6526A0FDDAEQ36069376-34F4686D-4DA3-46C8-BA2D-7DC233179AB7Q36130232-65D71F2A-74F0-477A-842B-7E0F8717720FQ36394292-7C385A32-C1B6-4BD3-8C69-93E8CB1AEA44Q36521930-DC6D6B31-F050-4866-8977-915D75A0F77FQ36689292-46B07283-9E00-4AC1-AF87-D63D03125FBCQ37084451-4B51848D-FBAF-49DA-BA35-3818E7E62376Q38217052-1A1D29B7-816E-4B4A-A21A-4EEA8F1F74D9Q38245382-3D72375A-E895-46E8-B222-18A00B6D45E9Q38256807-FCD19EFE-5865-4649-BA8A-DE5F6C990836Q38256860-2249ED31-6ECF-47E6-A1FD-1ADA36FE1DA9Q38362703-222B88BE-A8BE-4981-8AD7-520DBB36F870Q38500101-1D29EE83-9663-4D40-BA9B-5BA8CA0E9E78Q38624760-38F94C5B-2B0A-4447-BF34-A561C58CC1ECQ38685907-E7B7EAF4-BC55-45AA-B083-AFD0BAA7DA76Q38704232-92C346B1-8340-4EDB-8AA1-9A60E56CC3E8Q38726586-EC754164-CDCD-4DA1-AD09-6AED725B7C27Q38738480-30080432-393E-4BB3-9DAC-5BB1814AB3DFQ38738483-AEABF51D-599E-46B9-913B-2CB233BCE005Q38767526-D6AF7FD6-1154-43BC-B09D-4278FD11C74BQ38938423-15A72EBC-D21A-4492-A2B0-30A9911978A0Q39101941-86F45BCC-D781-4BEF-95DA-965D7E4A6397Q39122306-6E0B63A8-9749-4350-A926-E0B94C9B3CD5
P2860
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@en
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@nl
type
label
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@en
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@nl
prefLabel
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@en
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@nl
P2093
P921
P356
P1476
Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
@en
P2093
Bradley K Weiner
Branko Kopjar
Eric L Hurwitz
Eugene J Carragee
Garet Comer
Gilbert Chu
Rajat Rohatgi
S Tim Yoon
P2880
P304
P356
10.2106/JBJS.L.01483
P407
P577
2013-09-01T00:00:00Z